Suitability of computed tomography-guided biopsy specimens for subtyping and genotyping of non-small-cell lung cancer

Shih Hsin Hsiao, Chi Li Chung, Chi-Ming Lee, Wei Yu Chen, Yu Ting Chou, Zhung Han Wu, Yi Chie Chen, Sey En Lin

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction Recent advances in the treatment of NSCLC highlight the importance of distinguishing NSCLC subtypes and genotypes. We aimed to determine whether histological specimens obtained from computed tomography (CT)-guided biopsy are suitable for specific subtyping and epidermal growth factor receptor (EGFR) analyses of NSCLC. Patients and Methods The clinicohistological data of 332 consecutive patients undergoing 352 CT-guided biopsies for lung lesions between January 2007 and December 2011 were retrospectively analyzed. Additionally, NSCLC specimens were examined for the suitability of EGFR mutational testing. Results Of 209 specimens diagnosed as NSCLC, 197 (94.3%) were specifically subtyped into adenocarcinoma (n = 164; 78.5%), squamous cell carcinoma (n = 27; 12.9%) and other subtypes (n = 6; 2.9%). The rate of NSCLC not otherwise specified (NOS) was 5.7%, and the diagnosis of NSCLC-NOS was significantly associated with the poor differentiation of cancer (adjusted odds ratio, 6.17; 95% confidence interval, 1.62-23.55; P =.008). Of 134 histological tumor specimens submitted for EGFR molecular testing, 132 (98.5%) were suitable for analyses, and 130 of them (98.5%) showed conclusive results, revealing 59.8% (n = 79) with EGFR exon mutation(s). The sensitivity, specificity, and positive and negative predictive values of CT-guided biopsy in patients with malignancy were 92.2%, 100%, 100%, and 74.1%, respectively. Six percent (n = 21) of total lung biopsies led to pneumothorax requiring chest drainage, and no procedure-related fatality was observed. Conclusion Small tumor specimens obtained with CT-guided needle lung biopsy are suitable for specific subtyping and EGFR analyses of NSCLC, thus providing critical information for personalized therapy.

Original languageEnglish
Pages (from-to)719-725
Number of pages7
JournalClinical Lung Cancer
Volume14
Issue number6
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Tomography
Biopsy
Lung
Neoplasms
Needle Biopsy
Pneumothorax
Drainage
Squamous Cell Carcinoma
Exons
Adenocarcinoma
Thorax
Odds Ratio
Genotype
Confidence Intervals
Sensitivity and Specificity
Mutation
Therapeutics

Keywords

  • Epidermal growth factor receptor mutations
  • Genotyping
  • Non-small cell lung cancer
  • Subtyping

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Suitability of computed tomography-guided biopsy specimens for subtyping and genotyping of non-small-cell lung cancer. / Hsiao, Shih Hsin; Chung, Chi Li; Lee, Chi-Ming; Chen, Wei Yu; Chou, Yu Ting; Wu, Zhung Han; Chen, Yi Chie; Lin, Sey En.

In: Clinical Lung Cancer, Vol. 14, No. 6, 11.2013, p. 719-725.

Research output: Contribution to journalArticle

Hsiao, Shih Hsin ; Chung, Chi Li ; Lee, Chi-Ming ; Chen, Wei Yu ; Chou, Yu Ting ; Wu, Zhung Han ; Chen, Yi Chie ; Lin, Sey En. / Suitability of computed tomography-guided biopsy specimens for subtyping and genotyping of non-small-cell lung cancer. In: Clinical Lung Cancer. 2013 ; Vol. 14, No. 6. pp. 719-725.
@article{9d35e25036de405caeaaa6b2f73f02c3,
title = "Suitability of computed tomography-guided biopsy specimens for subtyping and genotyping of non-small-cell lung cancer",
abstract = "Introduction Recent advances in the treatment of NSCLC highlight the importance of distinguishing NSCLC subtypes and genotypes. We aimed to determine whether histological specimens obtained from computed tomography (CT)-guided biopsy are suitable for specific subtyping and epidermal growth factor receptor (EGFR) analyses of NSCLC. Patients and Methods The clinicohistological data of 332 consecutive patients undergoing 352 CT-guided biopsies for lung lesions between January 2007 and December 2011 were retrospectively analyzed. Additionally, NSCLC specimens were examined for the suitability of EGFR mutational testing. Results Of 209 specimens diagnosed as NSCLC, 197 (94.3{\%}) were specifically subtyped into adenocarcinoma (n = 164; 78.5{\%}), squamous cell carcinoma (n = 27; 12.9{\%}) and other subtypes (n = 6; 2.9{\%}). The rate of NSCLC not otherwise specified (NOS) was 5.7{\%}, and the diagnosis of NSCLC-NOS was significantly associated with the poor differentiation of cancer (adjusted odds ratio, 6.17; 95{\%} confidence interval, 1.62-23.55; P =.008). Of 134 histological tumor specimens submitted for EGFR molecular testing, 132 (98.5{\%}) were suitable for analyses, and 130 of them (98.5{\%}) showed conclusive results, revealing 59.8{\%} (n = 79) with EGFR exon mutation(s). The sensitivity, specificity, and positive and negative predictive values of CT-guided biopsy in patients with malignancy were 92.2{\%}, 100{\%}, 100{\%}, and 74.1{\%}, respectively. Six percent (n = 21) of total lung biopsies led to pneumothorax requiring chest drainage, and no procedure-related fatality was observed. Conclusion Small tumor specimens obtained with CT-guided needle lung biopsy are suitable for specific subtyping and EGFR analyses of NSCLC, thus providing critical information for personalized therapy.",
keywords = "Epidermal growth factor receptor mutations, Genotyping, Non-small cell lung cancer, Subtyping",
author = "Hsiao, {Shih Hsin} and Chung, {Chi Li} and Chi-Ming Lee and Chen, {Wei Yu} and Chou, {Yu Ting} and Wu, {Zhung Han} and Chen, {Yi Chie} and Lin, {Sey En}",
year = "2013",
month = "11",
doi = "10.1016/j.cllc.2013.06.002",
language = "English",
volume = "14",
pages = "719--725",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Suitability of computed tomography-guided biopsy specimens for subtyping and genotyping of non-small-cell lung cancer

AU - Hsiao, Shih Hsin

AU - Chung, Chi Li

AU - Lee, Chi-Ming

AU - Chen, Wei Yu

AU - Chou, Yu Ting

AU - Wu, Zhung Han

AU - Chen, Yi Chie

AU - Lin, Sey En

PY - 2013/11

Y1 - 2013/11

N2 - Introduction Recent advances in the treatment of NSCLC highlight the importance of distinguishing NSCLC subtypes and genotypes. We aimed to determine whether histological specimens obtained from computed tomography (CT)-guided biopsy are suitable for specific subtyping and epidermal growth factor receptor (EGFR) analyses of NSCLC. Patients and Methods The clinicohistological data of 332 consecutive patients undergoing 352 CT-guided biopsies for lung lesions between January 2007 and December 2011 were retrospectively analyzed. Additionally, NSCLC specimens were examined for the suitability of EGFR mutational testing. Results Of 209 specimens diagnosed as NSCLC, 197 (94.3%) were specifically subtyped into adenocarcinoma (n = 164; 78.5%), squamous cell carcinoma (n = 27; 12.9%) and other subtypes (n = 6; 2.9%). The rate of NSCLC not otherwise specified (NOS) was 5.7%, and the diagnosis of NSCLC-NOS was significantly associated with the poor differentiation of cancer (adjusted odds ratio, 6.17; 95% confidence interval, 1.62-23.55; P =.008). Of 134 histological tumor specimens submitted for EGFR molecular testing, 132 (98.5%) were suitable for analyses, and 130 of them (98.5%) showed conclusive results, revealing 59.8% (n = 79) with EGFR exon mutation(s). The sensitivity, specificity, and positive and negative predictive values of CT-guided biopsy in patients with malignancy were 92.2%, 100%, 100%, and 74.1%, respectively. Six percent (n = 21) of total lung biopsies led to pneumothorax requiring chest drainage, and no procedure-related fatality was observed. Conclusion Small tumor specimens obtained with CT-guided needle lung biopsy are suitable for specific subtyping and EGFR analyses of NSCLC, thus providing critical information for personalized therapy.

AB - Introduction Recent advances in the treatment of NSCLC highlight the importance of distinguishing NSCLC subtypes and genotypes. We aimed to determine whether histological specimens obtained from computed tomography (CT)-guided biopsy are suitable for specific subtyping and epidermal growth factor receptor (EGFR) analyses of NSCLC. Patients and Methods The clinicohistological data of 332 consecutive patients undergoing 352 CT-guided biopsies for lung lesions between January 2007 and December 2011 were retrospectively analyzed. Additionally, NSCLC specimens were examined for the suitability of EGFR mutational testing. Results Of 209 specimens diagnosed as NSCLC, 197 (94.3%) were specifically subtyped into adenocarcinoma (n = 164; 78.5%), squamous cell carcinoma (n = 27; 12.9%) and other subtypes (n = 6; 2.9%). The rate of NSCLC not otherwise specified (NOS) was 5.7%, and the diagnosis of NSCLC-NOS was significantly associated with the poor differentiation of cancer (adjusted odds ratio, 6.17; 95% confidence interval, 1.62-23.55; P =.008). Of 134 histological tumor specimens submitted for EGFR molecular testing, 132 (98.5%) were suitable for analyses, and 130 of them (98.5%) showed conclusive results, revealing 59.8% (n = 79) with EGFR exon mutation(s). The sensitivity, specificity, and positive and negative predictive values of CT-guided biopsy in patients with malignancy were 92.2%, 100%, 100%, and 74.1%, respectively. Six percent (n = 21) of total lung biopsies led to pneumothorax requiring chest drainage, and no procedure-related fatality was observed. Conclusion Small tumor specimens obtained with CT-guided needle lung biopsy are suitable for specific subtyping and EGFR analyses of NSCLC, thus providing critical information for personalized therapy.

KW - Epidermal growth factor receptor mutations

KW - Genotyping

KW - Non-small cell lung cancer

KW - Subtyping

UR - http://www.scopus.com/inward/record.url?scp=84887246299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887246299&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2013.06.002

DO - 10.1016/j.cllc.2013.06.002

M3 - Article

C2 - 23891241

AN - SCOPUS:84887246299

VL - 14

SP - 719

EP - 725

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 6

ER -